Description
Latin name
GROPRINOSIN
Release form
Tablets are white or almost white, oblong, biconvex, with a notch on one side.
Packing
10 pcs. – blisters (5) – packs of cardboard
Pharmacological action
Immunostimulating drug with antiviral effect. It is a complex containing inosine and a salt of 4-acetamidobenzoic acid with N, N-dimethylamino-2-propanol in a 1: 3 molar ratio.
The effectiveness of the complex is determined by the presence of inosine, the second component increases its availability for lymphocytes. Groprinosin blocks the reproduction of viral particles by damaging the genetic apparatus, stimulates macrophage activity, proliferation of lymphocytes and the formation of cytokines.
Reduces the clinical manifestations of viral diseases, accelerates convalescence, and increases the body’s resistance.
When prescribing Groprinosin as an auxiliary drug for infectious lesions of the mucous membranes and skin, caused by the Herpes simplex virus, more rapid healing of the affected surface occurs than with conventional treatment.
Less commonly, new vesicles, edema, erosion, and relapse of the disease occur. With timely use of the drug, the incidence of viral infections is reduced, the duration and severity of the disease is reduced.
Indications
immunodeficiency caused by viral infections in patients with normal and weakened immune systems, including diseases caused by Herpes simplex viruses types 1 and 2 (including genital herpes and herpes of a different localization)
subacute sclerosing panencephalitis.
Contraindications
gout
urolithiasis
arrhythmia
chronic renal failure
children under 3 years of age (body weight up to 15-20 kg)
pregnancy
lactation period (breastfeeding component).
Caution is advised to prescribe a drug with xanthine oxidase inhibitors, diuretics, zidovudine, in acute renal failure.
Use during pregnancy and lactation
The drug is contraindicated during pregnancy and during lactation (breastfeeding), because its safety in this category of patients has not been established.
Composition
Active ingredient:
inosine pranobex 500 mg
Excipients:
potato starch – 85 mg,
polyvinylpyrrolidone K25 – 45 mg,
magnesium stearate – 10 mg.
Dosage and administration
The drug is taken orally after a meal, at regular intervals (8 or 6 hours) 3-4 times / day.
Tablets are taken with a little water.
Adults are prescribed from 6 to 8 tablets / day in 3-4 doses.
Children aged 3 to 12 years are prescribed in a dose of 50 mg / kg / day, divided into 3-4 doses.
In both adults and children, in severe infectious diseases, the dose can be individually increased up to 100 mg / kg body weight / day, divided into 4-6 doses. The maximum daily dose in adults is 3-4 g, the maximum daily dose in children is 50 mg / kg.
In acute diseases, treatment usually lasts from 5 to 14 days. After the symptoms disappear, treatment should be continued for 1-2 days or more, depending on the indications.
In chronic relapsing diseases, treatment in adults and children is carried out in courses lasting 5-10 days at intervals of 8 days.
The duration of maintenance treatment can be up to 30 days, while the dose can be reduced to 0.5-1 g / day.
Treatment of herpes virus infections in adults and children: several courses should be taken, lasting 5-10 days until the symptoms disappear. To reduce the number of relapses, it is recommended to carry out maintenance treatment at 1 tab. 2 times / day for 30 days.
No need for dose adjustment in elderly patients, the drug is used in the same way as in middle-aged patients. In elderly patients, an increase in the concentration of uric acid in blood serum and urine occurs more often than in middle-aged patients.
The drug is used in children older than 3 years.
Against the background of treatment with Groprinosin in patients with hepatic insufficiency, uric acid in the blood serum and urine should be monitored every 2 weeks. Monitoring the activity of liver enzymes is recommended every 4 weeks with long courses of treatment with the drug.
Side effects
Side effects are defined as frequent (> 1/100 and <1/10) and infrequent (> 1/1000 and <1/1000). On the part of the nervous system: often – headache, dizziness, fatigue, poor health infrequently – nervousness, drowsiness, insomnia. From the gastrointestinal tract: often – decreased appetite, nausea, vomiting, epigastric pain infrequently – diarrhea, constipation. From the hepatobiliary system: often – increased activity of liver enzymes, alkaline phosphatase. From the skin and subcutaneous fat: often – itching, rash. From the kidneys and urinary tract: infrequently – polyuria. Allergic reactions: infrequently – maculopapular rash, urticaria, angioedema. From the musculoskeletal system: often – joint pain, exacerbation of gout. Other: often – increased blood urea nitrogen concentration. Drug Interaction Immunosuppressants attenuate the immunostimulatory effect of Groprinosin. Groprinosin should be used with caution in patients receiving concomitant xanthine oxidase inhibitors (allopurinol) or loop diuretics (furosemide, torasemide, ethacrynic acid), because this can lead to an increase in the concentration of uric acid in the serum. The combined use of the drug Groprinosin with zidovudine increases the concentration of zidovudine in the blood plasma and prolongs its half-life. Thus, when co-administered with Groprinosin with zidovudine, dose adjustment of zidovudine may be required. Overdose Overdose shows gastric lavage and symptomatic therapy. Storage conditions The drug should be stored out of the reach of children at a temperature not exceeding 30 ° C. Expiration 3 years. Deystvuyuschee substances Inosine Pranobex Pharmacy terms of sale Prescription dosage form dosage form tablets
